💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Indoco Remedies Limited is an India-based fully integrated, research-oriented pharmaceutical company. The Company is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs). The Company caters to both…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A weak business, reasonably priced.
Indoco Remedies is scored on the pharma / healthcare framework. It keeps a thin -5.3% of every rupee of sales as net profit. Free cash flow is worth about 4.5% of its market value.
Net worth has actually shrunk (-3%/yr) — value is not being built. Return on equity is a weak -7.7%. In the latest quarter profit fell 70% versus the prior quarter.
At 22× earnings, the stock sits at the 33rd percentile of its own 2-year range — the middle of where it has historically traded. Today's price already implies ~25%/yr earnings growth sustained for a decade — a demanding bar. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 62.82 | — | — |
| P/B | 1.95 | 4.1 | better |
| EV/EBITDA | 9.81 | 19.33 | better |
| ROE | -7.71 | 0.3 | worse |
| ROCE | 1.93 | — | — |
| ROA | 1.22 | 1.64 | worse |
| Quick Ratio | 0.75 | — | — |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
3% CAGR — growing but slowly. Growth is accelerating — latest year outpaced the prior year's rate.
2 of the 4 years shown had a loss — profitability is inconsistent.
Operating margin has compressed from 12% to -6% — costs or competition are eating into profitability. Interest or tax burden is shrinking — more of the operating profit is reaching the bottom line. Margins have declined for 3 consecutive years — watch for a structural cost problem.
Negative ROE — the business is destroying shareholder value. Capital efficiency declining — ROE down 24pp.
EPS dropped in the latest year despite possible profit changes — dilution or a profit dip could be at play. -32% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Heavy investing spend every year, but operations generate enough to cover it — the business self-funds its growth.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue rose 11% sequentially — momentum is building.
2 of 4 quarters loss-making — quarterly profitability is uneven. Profit fell 70% QoQ — one-quarter drops can be noise, but a pattern matters. Quarterly net margins are expanding (-7% → 4%) — profitability per rupee of revenue is improving.
How today's P/E compares to the stock's own historical range. Dashed line = the 2y median.
Promoter holding at 58.9% — majority control intact.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.